<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39380156</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".</ArticleTitle><Pagination><StartPage>e13314</StartPage><MedlinePgn>e13314</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13314</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.13314</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This report summarizes the discussions and conclusions from the "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID-19 Pandemic" meeting, which took place in Seattle, USA, from March 1, 2023, to March 3, 2023.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Discussions around influenza virus correlates of protection and their use continued from where the discussion had been left off in 2019. While there was not much progress in the influenza field itself, many lessons learned during the coronavirus disease 2019 (COVID-19) pandemic, especially the importance of mucosal immunity, were discussed and can directly be applied to influenza correlates of protection.</AbstractText><CopyrightInformation>© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krammer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>The Task Force for Global Health, Decatur, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Othmar G</ForeName><Initials>OG</Initials><AffiliationInfo><Affiliation>Science Research &amp; Innovation, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Diane J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (DMID/NIAID/NIH), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (DMID/NIAID/NIH), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sheena G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-0856-0294</Identifier><AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tompkins</LastName><ForeName>S Mark</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-1523-5588</Identifier><AffiliationInfo><Affiliation>Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Influenza Disease and Emergence Response (CIDER), University of Georgia, Athens, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz-Cherry</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Rebecca Jane</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-8341-4078</Identifier><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">correlates of protection (CoP)</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">influenza vaccine</Keyword><Keyword MajorTopicYN="N">mucosal immunity</Keyword></KeywordList><CoiStatement>The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccine and therapeutics, SARS‐CoV‐2 serological assays, and NDV‐based SARS‐CoV‐2 vaccines, which list Florian Krammer as co‐inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS‐CoV‐2. Dr. Krammer has consulted for Merck, Seqirus, CureVac, and Pfizer in the past and is currently consulting for Pfizer, 3rd Rock Ventures, GSK, and Avimex, and he is a cofounder and scientific advisory board member of CastleVax. The Krammer laboratory has also collaborated with Pfizer on animal models for SARS‐CoV‐2 and with GSK on influenza virus vaccine development in the past and is currently collaborating with Dynavax on influenza virus vaccine development. S.G.S. has consulted for Novavax, CSL Seqirus, Evo Health, Moderna, and Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380156</ArticleId><ArticleId IdType="pmc">PMC11461279</ArticleId><ArticleId IdType="doi">10.1111/irv.13314</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moore K. A., Leighton T., Ostrowsky J. T., et al., “A Research and Development (R&amp;D) Roadmap for Broadly Protective Coronavirus Vaccines: A Pandemic Preparedness Strategy,” Vaccine 41, no. 13 (2023): 2101–2112, 10.1016/j.vaccine.2023.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.032</ArticleId><ArticleId IdType="pmc">PMC9941884</ArticleId><ArticleId IdType="pubmed">36870874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson D., Curry R. L., Beare A. S., and Ward‐Gardner A., “The Role of Serum Haemagglutination‐Inhibiting Antibody in Protection Against Challenge Infection With Influenza A2 and B Viruses,” Epidemiology &amp; Infection 70, no. 4 (1972): 767–777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2130285</ArticleId><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S., Nachbagauer R., Balmaseda A., et al., “Novel Correlates of Protection Against Pandemic H1N1 Influenza A Virus Infection,” Nature Medicine 25, no. 6 (2019): 962–967, 10.1038/s41591-019-0463-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0463-x</ArticleId><ArticleId IdType="pmc">PMC6608747</ArticleId><ArticleId IdType="pubmed">31160818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowling B. J., Lim W. W., Perera R. A. P. M., et al., “Influenza Hemagglutination‐Inhibition Antibody Titer as a Mediator of Vaccine‐Induced Protection for Influenza B,” Clinical Infectious Diseases 68, no. 10 (2019): 1713–1717, 10.1093/cid/ciy759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy759</ArticleId><ArticleId IdType="pmc">PMC6495017</ArticleId><ArticleId IdType="pubmed">30202873</ArticleId></ArticleIdList></Reference><Reference><Citation>Black S., Nicolay U., Vesikari T., et al., “Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children,” The Pediatric Infectious Disease Journal 30, no. 12 (2011): 1081–1085, 10.1097/INF.0b013e3182367662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3182367662</ArticleId><ArticleId IdType="pubmed">21983214</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunning A. J., DiazGranados C. A., Voloshen T., Hu B., Landolfi V. A., and Talbot H. K., “Correlates of Protection Against Influenza in the Elderly: Results From an Influenza Vaccine Efficacy Trial,” Clinical and Vaccine Immunology 23, no. 3 (2016): 228–235, 10.1128/CVI.00604-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00604-15</ArticleId><ArticleId IdType="pmc">PMC4783426</ArticleId><ArticleId IdType="pubmed">26762363</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch R. B., Atmar R. L., Franco L. M., et al., “Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase,” The Journal of Infectious Diseases 207, no. 6 (2013): 974–981, 10.1093/infdis/jis935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis935</ArticleId><ArticleId IdType="pmc">PMC3633450</ArticleId><ArticleId IdType="pubmed">23307936</ArticleId></ArticleIdList></Reference><Reference><Citation>Monto A. S., Petrie J. G., Cross R. T., et al., “Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection,” The Journal of Infectious Diseases 212, no. 8 (2015): 1191–1199, 10.1093/infdis/jiv195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv195</ArticleId><ArticleId IdType="pubmed">25858957</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss C. D., Wang W., Lu Y., et al., “Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits,” Clinical Infectious Diseases 71, no. 12 (2020): 3096–3102, 10.1093/cid/ciz1198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1198</ArticleId><ArticleId IdType="pmc">PMC7819518</ArticleId><ArticleId IdType="pubmed">31840159</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschoor C. P., Singh P., Russell M. L., et al., “Microneutralization Assay Titres Correlate With Protection Against Seasonal Influenza H1N1 and H3N2 in Children,” PLoS ONE 10, no. 6 (2015): e0131531, 10.1371/journal.pone.0131531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131531</ArticleId><ArticleId IdType="pmc">PMC4479562</ArticleId><ArticleId IdType="pubmed">26107625</ArticleId></ArticleIdList></Reference><Reference><Citation>Grund S., Pietzonka S., Michel S., and Adams O., “Serum Antibodies Against Native and Denaturated Hemagglutinin Glycoproteins Detected by ELISA as Correlates of Protection After Influenza Vaccination in Healthy Vaccinees and in Kidney Transplant Recipients,” Journal of Virological Methods 193, no. 2 (2013): 558–564, 10.1016/j.jviromet.2013.07.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.07.032</ArticleId><ArticleId IdType="pubmed">23896019</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T., Escalera A., Strohmeier S., et al., “Pre‐Existing Hemagglutinin Stalk Antibodies Correlate With Protection of Lower Respiratory Symptoms in Flu‐Infected Transplant Patients,” Cell Reports Medicine 1, no. 8 (2020): 100130, 10.1016/j.xcrm.2020.100130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100130</ArticleId><ArticleId IdType="pmc">PMC7691380</ArticleId><ArticleId IdType="pubmed">33294855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T. M., Li C. K., Chui C. S., et al., “Preexisting Influenza‐Specific CD4+ T Cells Correlate With Disease Protection Against Influenza Challenge in Humans,” Nature Medicine 18, no. 2 (2012): 274–280, 10.1038/nm.2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2612</ArticleId><ArticleId IdType="pubmed">22286307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettelman R. C., Souquette A., van de Velde L. A., et al., “Baseline Innate and T Cell Populations Are Correlates of Protection Against Symptomatic Influenza Virus Infection Independent of Serology,” Nature Immunology 24, no. 9 (2023): 1511–1526, 10.1038/s41590-023-01590-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01590-2</ArticleId><ArticleId IdType="pmc">PMC10566627</ArticleId><ArticleId IdType="pubmed">37592015</ArticleId></ArticleIdList></Reference><Reference><Citation>McMichael A. J., Gotch F. M., Noble G. R., and Beare P. A., “Cytotoxic T‐Cell Immunity to Influenza,” The New England Journal of Medicine 309, no. 1 (1983): 13–17, 10.1056/NEJM198307073090103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198307073090103</ArticleId><ArticleId IdType="pubmed">6602294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen H., Rajendran M., Choi A., et al., “Influenza Virus Hemagglutinin Stalk‐Specific Antibodies in Human Serum Are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model,” MBio 8, no. 5 (2017), 10.1128/mBio.01463-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01463-17</ArticleId><ArticleId IdType="pmc">PMC5605943</ArticleId><ArticleId IdType="pubmed">28928215</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgar J. E., Trezise S., Anthony R. M., et al., “Antibodies Elicited in Humans Upon Chimeric Hemagglutinin‐Based Influenza Virus Vaccination Confer FcγR‐Dependent Protection In Vivo,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 44 (2023): e2314905120, 10.1073/pnas.2314905120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2314905120</ArticleId><ArticleId IdType="pmc">PMC10622865</ArticleId><ArticleId IdType="pubmed">37871218</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S. A., “Correlates of Protection Induced by Vaccination,” Clinical and Vaccine Immunology 17, no. 7 (2010): 1055–1065, 10.1128/CVI.00131-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00131-10</ArticleId><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S. A. and Gilbert P. B., “Nomenclature for Immune Correlates of Protection After Vaccination,” Clinical Infectious Diseases 54, no. 11 (2012): 1615–1617, 10.1093/cid/cis238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis238</ArticleId><ArticleId IdType="pmc">PMC3348952</ArticleId><ArticleId IdType="pubmed">22437237</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh‐Mohamed S., Sanders E. C., Gommerman J. L., and Tal M. C., “Guardians of the Oral and Nasopharyngeal Galaxy: IgA and Protection Against SARS‐CoV‐2 Infection,” Immunological Reviews 309, no. 1 (2022): 75–85, 10.1111/imr.13118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13118</ArticleId><ArticleId IdType="pmc">PMC9349649</ArticleId><ArticleId IdType="pubmed">35815463</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Weir J. P., Engelhardt O., Katz J. M., and Cox R. J., “Meeting Report and Review: Immunological Assays and Correlates of Protection for Next‐Generation Influenza Vaccines,” Influenza and Other Respiratory Viruses 14 (2019): 237–243, 10.1111/irv.12706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12706</ArticleId><ArticleId IdType="pmc">PMC7040967</ArticleId><ArticleId IdType="pubmed">31837101</ArticleId></ArticleIdList></Reference><Reference><Citation>Killingley B., Mann A. J., Kalinova M., et al., “Safety, Tolerability and Viral Kinetics During SARS‐CoV‐2 Human Challenge in Young Adults,” Nature Medicine 28, no. 5 (2022): 1031–1041, 10.1038/s41591-022-01780-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01780-9</ArticleId><ArticleId IdType="pubmed">35361992</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnink W. F., Stadlbauer D., Puente‐Massaguer E., et al., “Characterization of Non‐Neutralizing Human Monoclonal Antibodies That Target the M1 and NP of Influenza A Viruses,” Journal of Virology 97, no. 11 (2023): e0164622, 10.1128/jvi.01646-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01646-22</ArticleId><ArticleId IdType="pmc">PMC10688359</ArticleId><ArticleId IdType="pubmed">37916834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusi K. A., Faber B. W., Koopman G., and Remarque E. J., “EDiP: The Epitope Dilution Phenomenon. Lessons Learnt From a Malaria Vaccine Antigen and Its Applicability to Polymorphic Antigens,” Expert Review of Vaccines 17, no. 1 (2018): 13–21, 10.1080/14760584.2018.1411198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1411198</ArticleId><ArticleId IdType="pubmed">29224404</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A. M., Baranowska‐Hustad M., Braathen R., Grodeland G., and Bogen B., “Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity Against Influenza,” Journal of Immunology 200, no. 6 (2018): 2057–2066, 10.4049/jimmunol.1701088.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1701088</ArticleId><ArticleId IdType="pmc">PMC5834789</ArticleId><ArticleId IdType="pubmed">29427414</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., “Strategies to Induce Broadly Protective Antibody Responses to Viral Glycoproteins,” Expert Review of Vaccines 16, no. 5 (2017): 503–513, 10.1080/14760584.2017.1299576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1299576</ArticleId><ArticleId IdType="pubmed">28277797</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier H. E., Nachbagauer R., Kuan G., et al., “Pre‐Existing Anti‐Neuraminidase Antibodies Are Associated With Shortened Duration of Influenza A (H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults,” Clinical Infectious Diseases 70, (2019): 2290–2297, 10.1093/cid/ciz639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz639</ArticleId><ArticleId IdType="pmc">PMC7245146</ArticleId><ArticleId IdType="pubmed">31300819</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudreau C. M. and Alter G., “Extra‐Neutralizing FcR‐Mediated Antibody Functions for a Universal Influenza Vaccine,” Frontiers in Immunology 10, (2019): 440, 10.3389/fimmu.2019.00440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00440</ArticleId><ArticleId IdType="pmc">PMC6436086</ArticleId><ArticleId IdType="pubmed">30949165</ArticleId></ArticleIdList></Reference><Reference><Citation>Havenar‐Daughton C., Newton I. G., Zare S. Y., et al., “Normal Human Lymph Node T Follicular Helper Cells and Germinal Center B Cells Accessed via Fine Needle Aspirations,” Journal of Immunological Methods 479, (2020): 112746, 10.1016/j.jim.2020.112746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2020.112746</ArticleId><ArticleId IdType="pmc">PMC7200018</ArticleId><ArticleId IdType="pubmed">31958451</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J. S., Zhou J. Q., Han J., et al., “Human Germinal Centres Engage Memory and Naive B Cells After Influenza Vaccination,” Nature 586, no. 7827 (2020): 127–132, 10.1038/s41586-020-2711-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2711-0</ArticleId><ArticleId IdType="pmc">PMC7566073</ArticleId><ArticleId IdType="pubmed">32866963</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J. S., Kim W., Kalaidina E., et al., “SARS‐CoV‐2 Infection Induces Long‐Lived Bone Marrow Plasma Cells in Humans,” Nature 595 (2021): 421–425, 10.1038/s41586-021-03647-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03647-4</ArticleId><ArticleId IdType="pubmed">34030176</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S., “T Follicular Helper Cell Biology: A Decade of Discovery and Diseases,” Immunity 50, no. 5 (2019): 1132–1148, 10.1016/j.immuni.2019.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.011</ArticleId><ArticleId IdType="pmc">PMC6532429</ArticleId><ArticleId IdType="pubmed">31117010</ArticleId></ArticleIdList></Reference><Reference><Citation>Souquette A., Allen E. K., Oshansky C. M., et al., “Integrated Drivers of Basal and Acute Immunity in Diverse Human Populations,” bioRxiv (2023), 10.1101/2023.03.25.534227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.25.534227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P. A., Minervina A. A., Pogorelyy M. V., et al., “SARS‐CoV‐2 mRNA Vaccination Elicits a Robust and Persistent T Follicular Helper Cell Response in Humans,” Cell 185, no. 4 (2022): 603–613.e15, 10.1016/j.cell.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8695127</ArticleId><ArticleId IdType="pubmed">35026152</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J. M., Mateus J., Kato Y., et al., “Immunological Memory to SARS‐CoV‐2 Assessed for up to 8 Months After Infection,” Science 371, (2021): eabf4063, 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., Sutton H. J., Cottrell C. A., et al., “Long‐Primed Germinal Centres With Enduring Affinity Maturation and Clonal Migration,” Nature 609, no. 7929 (2022): 998–1004, 10.1038/s41586-022-05216-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05216-9</ArticleId><ArticleId IdType="pmc">PMC9491273</ArticleId><ArticleId IdType="pubmed">36131022</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites R. S., Jarvis H. C., Singh N., et al., “Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples,” Journal of Visualized Experiments 131, (2018), 10.3791/56413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/56413</ArticleId><ArticleId IdType="pmc">PMC5908664</ArticleId><ArticleId IdType="pubmed">29443104</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites R. S., Uruchurtu A. S. S., Negri V. A., et al., “Early Mucosal Events Promote Distinct Mucosal and Systemic Antibody Responses to Live Attenuated Influenza Vaccine,” Nature Communications 14, no. 1 (2023): 8053, 10.1038/s41467-023-43842-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43842-7</ArticleId><ArticleId IdType="pmc">PMC10697962</ArticleId><ArticleId IdType="pubmed">38052824</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements M. L., Betts R. F., Tierney E. L., and Murphy B. R., “Serum and Nasal Wash Antibodies Associated With Resistance to Experimental Challenge With Influenza A Wild‐Type Virus,” Journal of Clinical Microbiology 24, no. 1 (1986): 157–160, 10.1128/jcm.24.1.157-160.1986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.24.1.157-160.1986</ArticleId><ArticleId IdType="pmc">PMC268857</ArticleId><ArticleId IdType="pubmed">3722363</ArticleId></ArticleIdList></Reference><Reference><Citation>Belshe R. B., Gruber W. C., Mendelman P. M., et al., “Correlates of Immune Protection Induced by Live, Attenuated, Cold‐Adapted, Trivalent, Intranasal Influenza Virus Vaccine,” The Journal of Infectious Diseases 181, no. 3 (2000): 1133–1137, 10.1086/315323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315323</ArticleId><ArticleId IdType="pubmed">10720541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrose C. S., Wu X., Jones T., and Mallory R. M., “The Role of Nasal IgA in Children Vaccinated With Live Attenuated Influenza Vaccine,” Vaccine 30, no. 48 (2012): 6794–6801, 10.1016/j.vaccine.2012.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.018</ArticleId><ArticleId IdType="pubmed">23000125</ArticleId></ArticleIdList></Reference><Reference><Citation>Barría M. I., Garrido J. L., Stein C., et al., “Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults,” The Journal of Infectious Diseases 207, no. 1 (2013): 115–124, 10.1093/infdis/jis641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis641</ArticleId><ArticleId IdType="pmc">PMC3571238</ArticleId><ArticleId IdType="pubmed">23087433</ArticleId></ArticleIdList></Reference><Reference><Citation>Panapasa J. A., Cox R. J., Mohn K. G., Aqrawi L. A., and Brokstad K. A., “The Expression of B &amp; T Cell Activation Markers in Children's Tonsils Following Live Attenuated Influenza Vaccine,” Human Vaccines &amp; Immunotherapeutics 11, no. 7 (2015): 1663–1672, 10.1080/21645515.2015.1032486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1032486</ArticleId><ArticleId IdType="pmc">PMC4514187</ArticleId><ArticleId IdType="pubmed">26148331</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljurayyan A., Puksuriwong S., Ahmed M., et al., “Activation and Induction of Antigen‐Specific T Follicular Helper Cells Play a Critical Role in Live‐Attenuated Influenza Vaccine‐Induced Human Mucosal Anti‐Influenza Antibody Response,” Journal of Virology 92, no. 11 (2018), 10.1128/JVI.00114-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00114-18</ArticleId><ArticleId IdType="pmc">PMC5952133</ArticleId><ArticleId IdType="pubmed">29563292</ArticleId></ArticleIdList></Reference><Reference><Citation>Lartey S., Zhou F., Brokstad K. A., et al., “Live‐Attenuated Influenza Vaccine Induces Tonsillar Follicular T Helper Cell Responses That Correlate With Antibody Induction,” The Journal of Infectious Diseases 221, no. 1 (2020): 21–32, 10.1093/infdis/jiz321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz321</ArticleId><ArticleId IdType="pmc">PMC6910880</ArticleId><ArticleId IdType="pubmed">31250024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohn K. G., Brokstad K. A., Pathirana R. D., et al., “Live Attenuated Influenza Vaccine in Children Induces B‐Cell Responses in Tonsils,” The Journal of Infectious Diseases 214, no. 5 (2016): 722–731, 10.1093/infdis/jiw230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw230</ArticleId><ArticleId IdType="pmc">PMC4978372</ArticleId><ArticleId IdType="pubmed">27247344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegaskanda S., Mason R. D., Andrews S. F., et al., “Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes,” Journal of Virology 92, no. 9 (2018), 10.1128/JVI.01970-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01970-17</ArticleId><ArticleId IdType="pmc">PMC5899203</ArticleId><ArticleId IdType="pubmed">29444938</ArticleId></ArticleIdList></Reference><Reference><Citation>Brokstad K. A., Eriksson J. C., Cox R. J., et al., “Parenteral Vaccination against Influenza Does Not Induce a Local Antigen‐Specific Immune Response in the Nasal Mucosa,” The Journal of Infectious Diseases 185, no. 7 (2002): 878–884, 10.1086/339710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/339710</ArticleId><ArticleId IdType="pubmed">11920311</ArticleId></ArticleIdList></Reference><Reference><Citation>el‐Madhun A. S., Cox R. J., Søreide A., Olofsson J., and Haaheim L. R., “Systemic and Mucosal Immune Responses in Young Children and Adults After Parenteral Influenza Vaccination,” The Journal of Infectious Diseases 178, no. 4 (1998): 933–939, 10.1086/515656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/515656</ArticleId><ArticleId IdType="pubmed">9806018</ArticleId></ArticleIdList></Reference><Reference><Citation>Isho B., Abe K. T., Zuo M., et al., “Persistence of Serum and Saliva Antibody Responses to SARS‐CoV‐2 Spike Antigens in COVID‐19 Patients,” Science Immunology 5, no. 52 (2020), 10.1126/sciimmunol.abe5511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe5511</ArticleId><ArticleId IdType="pmc">PMC8050884</ArticleId><ArticleId IdType="pubmed">33033173</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F., Talwar S., Cross A., et al., “SARS‐CoV‐2‐Specific Nasal IgA Wanes 9 Months After Hospitalisation With COVID‐19 and Is Not Induced by Subsequent Vaccination,” eBioMedicine 87, (2023): 104402, 10.1016/j.ebiom.2022.104402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104402</ArticleId><ArticleId IdType="pmc">PMC9762734</ArticleId><ArticleId IdType="pubmed">36543718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh‐Mohamed S., Isho B., Chao G. Y. C., et al., “Systemic and Mucosal IgA Responses Are Variably Induced in Response to SARS‐CoV‐2 mRNA Vaccination and Are Associated With Protection Against Subsequent Infection,” Mucosal Immunology 15, no. 5 (2022): 799–808, 10.1038/s41385-022-00511-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-022-00511-0</ArticleId><ArticleId IdType="pmc">PMC9037584</ArticleId><ArticleId IdType="pubmed">35468942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano K., Bhavsar D., Singh G., et al., “SARS‐CoV‐2 Vaccination Induces Mucosal Antibody Responses in Previously Infected Individuals,” Nature Communications 13, no. 1 (2022): 5135, 10.1038/s41467-022-32389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32389-8</ArticleId><ArticleId IdType="pmc">PMC9435409</ArticleId><ArticleId IdType="pubmed">36050304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavsar D., Singh G., Sano K., et al., “Mucosal Antibody Responses to SARS‐CoV‐2 Booster Vaccination and Breakthrough Infection,” MBio 14, (2023): e0228023, 10.1128/mbio.02280-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.02280-23</ArticleId><ArticleId IdType="pmc">PMC10790573</ArticleId><ArticleId IdType="pubmed">38092666</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S., Marking U., Svensson J., et al., “Anti‐Spike Mucosal IgA Protection Against SARS‐CoV‐2 Omicron Infection,” The New England Journal of Medicine 387, no. 14 (2022): 1333–1336, 10.1056/NEJMc2209651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209651</ArticleId><ArticleId IdType="pmc">PMC9511632</ArticleId><ArticleId IdType="pubmed">36103621</ArticleId></ArticleIdList></Reference><Reference><Citation>Roubidoux E. K., Brigleb P. H., Vegesana K., et al., “Utility of Nasal Swabs for Assessing Mucosal Immune Responses Towards SARS‐CoV‐2,” Scientific Reports 13, no. 1 (2023): 17820, 10.1038/s41598-023-44989-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-44989-5</ArticleId><ArticleId IdType="pmc">PMC10587113</ArticleId><ArticleId IdType="pubmed">37857783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P. B., Montefiori D. C., McDermott A. B., et al., “Immune Correlates Analysis of the mRNA‐1273 COVID‐19 Vaccine Efficacy Clinical Trial,” Science 375, no. 6576 (2022): 43–50, 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldock J., Remarque E. J., Zheng L., et al., “Haemagglutination Inhibition and Virus Microneutralisation Serology Assays: Use of Harmonised Protocols and Biological Standards in Seasonal Influenza Serology Testing and Their Impact on Inter‐Laboratory Variation and Assay Correlation: A FLUCOP Collaborative Study,” Frontiers in Immunology 14, (2023): 1155552, 10.3389/fimmu.2023.1155552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1155552</ArticleId><ArticleId IdType="pmc">PMC10151801</ArticleId><ArticleId IdType="pubmed">37143658</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño J. M., McDonald J. U., Hurst T., et al., “Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk‐Reactive Antibodies,” Vaccines (Basel) 8, no. 4 (2020): 666, 10.3390/vaccines8040666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040666</ArticleId><ArticleId IdType="pmc">PMC7712758</ArticleId><ArticleId IdType="pubmed">33182279</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Fouchier R. A. M., Eichelberger M. C., et al., “NAction! How Can Neuraminidase‐Based Immunity Contribute to Better Influenza Virus Vaccines?” MBio 9, no. 2 (2018), 10.1128/mBio.02332-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02332-17</ArticleId><ArticleId IdType="pmc">PMC5885027</ArticleId><ArticleId IdType="pubmed">29615508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard M. C., Waldock J., Commandeur S., et al., “Validation of a Harmonized Enzyme‐Linked‐Lectin‐Assay (ELLA‐NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA‐NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study,” Frontiers in Immunology 13, (2022): 909297, 10.3389/fimmu.2022.909297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.909297</ArticleId><ArticleId IdType="pmc">PMC9248865</ArticleId><ArticleId IdType="pubmed">35784305</ArticleId></ArticleIdList></Reference><Reference><Citation>Waerlop G., Leroux‐Roels G., Lambe T., et al., “Harmonization and Qualification of an IFN‐γ Enzyme‐Linked ImmunoSpot Assay (ELISPOT) to Measure Influenza‐Specific Cell‐Mediated Immunity Within the FLUCOP Consortium,” Frontiers in Immunology 13, (2022): 984642, 10.3389/fimmu.2022.984642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.984642</ArticleId><ArticleId IdType="pmc">PMC9493492</ArticleId><ArticleId IdType="pubmed">36159843</ArticleId></ArticleIdList></Reference><Reference><Citation>Begue S., Waerlop G., Salaun B., et al., “Harmonization and Qualification of Intracellular Cytokine Staining to Measure Influenza‐Specific CD4,” Frontiers in Immunology 13, (2022): 982887, 10.3389/fimmu.2022.982887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.982887</ArticleId><ArticleId IdType="pmc">PMC9632653</ArticleId><ArticleId IdType="pubmed">36341380</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Steain M., Reynaldi A., et al., “Predicting Vaccine Effectiveness Against Severe COVID‐19 Over Time and Against Variants: A Meta‐Analysis,” Nature Communications 14, no. 1 (2023): 1633, 10.1038/s41467-023-37176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37176-7</ArticleId><ArticleId IdType="pmc">PMC10036966</ArticleId><ArticleId IdType="pubmed">36964146</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D. S., Docken S. S., Subbarao K., Kent S. J., Davenport M. P., and Cromer D., “Predicting the Efficacy of Variant‐Modified COVID‐19 Vaccine Boosters,” Nature Medicine 29, no. 3 (2023): 574–578, 10.1038/s41591-023-02228-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02228-4</ArticleId><ArticleId IdType="pubmed">36864253</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., “The Role of Vaccines in the COVID‐19 Pandemic: What Have We Learned?” Seminars in Immunopathology (2023), 10.1007/s00281-023-00996-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-023-00996-2</ArticleId><ArticleId IdType="pmc">PMC11136744</ArticleId><ArticleId IdType="pubmed">37436465</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle K. A., Ambrosino D. M., Fiore‐Gartland A., et al., “Evidence for Antibody as a Protective Correlate for COVID‐19 Vaccines,” Vaccine 39, (2021): 4423–4428, 10.1016/j.vaccine.2021.05.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.063</ArticleId><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Fiore‐Gartland A., Johnson M., et al., “Towards a Population‐Based Threshold of Protection for COVID‐19 Vaccines,” Vaccine 40, no. 2 (2022): 306–315, 10.1016/j.vaccine.2021.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.12.006</ArticleId><ArticleId IdType="pmc">PMC8673730</ArticleId><ArticleId IdType="pubmed">34933765</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Yu J., Mercado N. B., et al., “Correlates of Protection Against SARS‐CoV‐2 in Rhesus Macaques,” Nature 590, no. 7847 (2021): 630–634, 10.1038/s41586-020-03041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D. S., Cromer D., Reynaldi A., et al., “Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS‐CoV‐2 Infection,” Nature Medicine 27 (2021): 1205–1211, 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Vikström L., Fjällström P., Gwon Y. D., et al., “Vaccine‐Induced Correlate of Protection Against Fatal COVID‐19 in Older and Frail Adults During Waves of Neutralization‐Resistant Variants of Concern: An Observational Study,” The Lancet Regional Health–Europe 30, (2023): 100646, 10.1016/j.lanepe.2023.100646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100646</ArticleId><ArticleId IdType="pmc">PMC10163377</ArticleId><ArticleId IdType="pubmed">37363799</ArticleId></ArticleIdList></Reference><Reference><Citation>Marking U., Bladh O., Havervall S., et al., “7‐Month Duration of SARS‐CoV‐2 Mucosal Immunoglobulin‐A Responses and Protection,” The Lancet Infectious Diseases 23, (2023): 150–152, 10.1016/S1473-3099(22)00834-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00834-9</ArticleId><ArticleId IdType="pmc">PMC9833832</ArticleId><ArticleId IdType="pubmed">36640796</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., “SARS‐CoV‐2 Vaccines in Development,” Nature 586, no. 7830 (2020): 516–527, 10.1038/s41586-020-2798-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>